[Skip to Content]
[Skip to Content Landing]
Views 1,084
Citations 0
JAMA Clinical Guidelines Synopsis
May 17, 2016

Surveillance Imaging in Patients in Remission From Hodgkin and Diffuse Large B-Cell Lymphoma

Author Affiliations
  • 1Section of Hematology and Oncology, University of Chicago, Chicago, Illinois
  • 2Section of General Internal Medicine, University of Chicago, Chicago, Illinois
JAMA. 2016;315(19):2115-2116. doi:10.1001/jama.2016.4913

Lymphomas are divided into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), together affecting 80 000 US patients.1 Although most patients with HL are cured with initial chemotherapy with or without radiation, curability depends on disease subtype and prognostic parameters. Non-Hodgkin lymphoma is categorized into indolent and aggressive subtypes; diffuse large B-cell lymphoma (DLBCL) is most common and the prototype of aggressive histologies. About 15% to 20% of patients with HL and 30% to 40% of patients with DLBCL relapse after initial therapy.1 Patients relapsing with HL and DLBCL are offered autologous stem cell transplantation, which can cure approximately 40% of DLBCL and 50% to 70% of HL.1

First Page Preview View Large
First page PDF preview
First page PDF preview